FinkbohnerRJohnstonDCrawfordES, et al.Marfan syndrome. Long-term survival and complications after aortic aneurysm repair. Circulation1995; 91: 728–733.
3.
SilvermanDIBurtonKJGrayJ, et al.Life expectancy in the Marfan syndrome. Am J Cardiol1995; 75: 157–160.
4.
SalvadorGLMarmentiniVMCosmoWR, et al.Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis. Eur J Prev Cardiol2017; 24: 1914–1924.
5.
Fontes-CarvalhoR. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in the treatment of hypertension: Adding more fuel for the fire?Eur J Prev Cardiol2017; 24: 1911–1913.
6.
LiLYamaniNAl-NaimatS, et al.Role of losartan in prevention of aortic dilatation in Marfan syndrome: A systematic review and meta-analysis. Eur J Prev Cardiol 2020; 27: 1447–1450.
7.
HabashiJPJudgeDPHolmTM, et al.Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science2006; 312: 117–121.
8.
MalikAHYandrapalliSAronowWS, et al.Meta-analysis of direct-acting oral anticoagulants compared with warfarin in patients >75 years of age. Am J Cardiol2019; 123: 2051–2057.
9.
MalikAHYandrapalliSAronowWS, et al.Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves. Heart2019; 105: 1432–1436.
10.
TaherniaAC. Cardiovascular anomalies in Marfan's syndrome: The role of echocardiography and beta-blockers. South Med J1993; 86: 305–310.
11.
ChiuHHWuMHWangJK, et al.Losartan added to beta-blockade therapy for aortic root dilation in Marfan syndrome: A randomized, open-label pilot study. Mayo Clin Proc2013; 88: 271–276.
12.
GroeninkMden HartogAWFrankenR, et al.Losartan reduces aortic dilatation rate in adults with Marfan syndrome: A randomized controlled trial. Eur Heart J2013; 34: 3491–3500.
13.
SandorGGAlghamdiMHRaffinLA, et al.A randomized, double blind pilot study to assess the effects of losartan vs. atenolol on the biophysical properties of the aorta in patients with Marfan and Loeys-Dietz syndromes. Int J Cardiol2015; 179: 470–475.
14.
LacroRVGueyLTDietzHC, et al.Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy. Am Heart J2013; 165: 828–835.e3.
15.
BhattABBuckJSZuflachtJP, et al.Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome. Vasc Med2015; 20: 317–325.
16.
MilleronOArnoultFRopersJ, et al.Marfan Sartan: A randomized, double-blind, placebo-controlled trial. Eur Heart J2015; 36: 2160–2166.
17.
FortezaAEvangelistaASanchezV, et al.Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: A randomized clinical trial. Eur Heart J2016; 37: 978–985.
18.
Muiño-MosqueraLde NobeleSDevosD, et al.Efficacy of losartan as add-on therapy to prevent aortic growth and ventricular dysfunction in patients with Marfan syndrome: A randomized, double-blind clinical trial. Acta Cardiol2017; 72: 616–624.
19.
Mullen M. Hot Line Session 5. European Society of Cardiology Congress, Munich, 25–29 August 2018.
20.
RomanMJRosenSEKramer-FoxR, et al.Prognostic significance of the pattern of aortic root dilation in the Marfan syndrome. J Am Coll Cardiol1993; 22: 1470–1476.
